Results 1 to 10 of about 3,650 (207)

Depot medroxyprogesterone acetate and breast cancer: a systematic review. [PDF]

Arch Gynecol Obstet, 2023
Abstract Purpose Short-acting progestin-only injectables containing depot medroxyprogesterone acetate (DMPA) are a safe method of contraception. Although DMPA has been available for several decades, there is little data on its influence on the risk of breast cancer. Hence, the aim of this paper was to provide an overview
Zürcher A, Knabben L, von Gernler M, Stute P.   +3 more
europepmc   +5 more sources

Contraception in adolescents with mental disorders: adherence and satisfaction in the use of depot medroxyprogesterone acetate [PDF]

Revista Brasileira de Ginecologia e Obstetrícia
Objective: To evaluate the continuation rate, satisfaction, and reasons for discontinuation of depot medroxyprogesterone acetate (DMPA) in adolescents treated in a mental health service.
Giani Silvana Schwengber Cezimbra, Edward Araujo Júnior, Cristina Aparecida Falbo Guazzelli   +2 more
doaj   +3 more sources

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial [PDF]

Contraception, 2016
To describe medroxyprogesterone acetate (MPA) levels among Kenyan depot medroxyprogesterone acetate (DMPA) users in the FEM-PrEP HIV prevention trial, and to compare MPA levels between ARV for HIV prevention (treatment) and placebo groups.We measured MPA in previously collected plasma samples from 63 Kenyan trial participants who used DMPA for one or ...
Rebecca L Callahan, Kawango Ågot, David Jenkins   +2 more
exaly   +4 more sources

Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women

Emerging Microbes and Infections, 2019
The use of depot medroxyprogesterone acetate (DMPA), a 3-monthly injectable hormonal contraceptive, is associated with an increased risk of HIV acquisition possibly through alteration of the vaginal microbiome.
Yuhan Hao, Jiyuan Hu, Dervla Kelly
exaly   +4 more sources

Depot medroxyprogesterone acetate (DMPA)-associated early-onset osteoporotic fracture [PDF]

Endocrinology, Diabetes & Metabolism Case Reports
Depot medroxyprogesterone acetate (DMPA) is a highly effective injectable contraceptive, but is associated with reduced bone mineral density (BMD) and increased fracture risk in some studies because it inhibits the hypothalamic–pituitary–ovarian axis ...
Yotsapon Thewjitcharoen, Veekij Veerasomboonsin, Soontaree Nakasatien, Thep Himathongkam   +3 more
doaj   +2 more sources

Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate. [PDF]

PLoS Pathogens, 2022
Depot medroxyprogesterone acetate (DMPA) is an injectable hormonal contraceptive used by millions of women worldwide. However, experimental studies have associated DMPA use with genital epithelial barrier disruption and mucosal influx of human ...
Frideborg Bradley, Mathias Franzén Boger, Vilde Kaldhusdal, Alexandra Åhlberg, Gabriella Edfeldt, Julie Lajoie, Sofia Bergström, Kenneth Omollo, Anastasios Damdimopoulos, Paulo Czarnewski, Anna Månberg, Julius Oyugi, Joshua Kimani, Peter Nilsson, Keith Fowke, Annelie Tjernlund, Kristina Broliden   +16 more
doaj   +2 more sources

Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review [PDF]

Systematic Reviews, 2023
Background Self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception (DMPA-SC) is registered in many countries. It shows great potential for improving contraceptive access, continuation, and autonomy.
Adeniyi Kolade Aderoba, Petrus Schoken Steyn, James Njogu Kiarie   +2 more
doaj   +2 more sources

Cervical Secretions from Women After Depot Medroxyprogesterone Acetate (Depo-Provera) Administration Promote HIV Infectivity Ex Vivo [PDF]

Viruses
Depot medroxyprogesterone acetate (Depo-Provera) has been associated with an increased risk of HIV acquisition. We have previously shown that Depo-Provera administration increases immune markers for HIV preference on peripheral and cervical CD4+ T cells ...
Carley Tasker, Natalie E. Roche, Yungtai Lo, Theresa L. Chang   +3 more
doaj   +2 more sources

A Comparative Evaluation of Cut 380A Intrauterine Device Versus Depot Medroxyprogesterone Acetate For Long-Acting Reversible Contraception

Journal of Pharmacy and Bioallied Sciences
Background: India’s family-planning program increasingly emphasizes long-acting reversible contraceptives (LARCs) to curb unintended pregnancy. Copper T 380A (CuT 380A) intrauterine device (IUCD) and injectable depot medroxyprogesterone acetate (DMPA ...
Manisha Meena, Rupali Dewan
doaj   +2 more sources

Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis

BMC Women's Health, 2021
Background Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. A trained person can administer it, including women through self-injection.
Ashraf Nabhan, Farida Elshafeey, Luna Marion Mehrain, Rita Kabra, Amal Elshabrawy   +4 more
doaj   +1 more source